Project Description
The said Canadian biotech company was established in Jan 2023 with the goal of treating patients with inflammatory bowel disease (IBD). Unlike other medicines, they take on a more tailored and personalized approach by using Genetically Modified Microbial Medicines (GEMM™). Their GEMMs can be used for an array of hosts with inflammatory diseases and metabolic disorders, including GEMMs for humans or animals such as horses, pigs, and cats/dogs.
Mission
To revolutionize microbiome-based therapy through the power of GEMM™
Company Valuation
CA$ 100 mil
Key Driver for Valuation
